VECT VectivBio Holding AG

14.95
+1.18  (+9%)
Previous Close 13.77
Open 13.49
52 Week Low 12.6201
52 Week High 37.6999
Market Cap $536,134,927
Shares 35,861,868
Float 23,920,345
Enterprise Value $453,757,922
Volume 43,639
Av. Daily Volume 148,953
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Apraglutide
Short bowel syndrome - colon-in-continuity anatomy
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Apraglutide (STARS)
Short Bowel Syndrome
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. BOSTON and LONDON, May 5, 2021 /PRNewswire/ -- The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, announces the appointment of Luca Santarelli, M.D., as new Chair of its Scientific Advisory Board (SAB). 

    Dr. Santarelli is an entrepreneurial pharmaceutical executive with a background in academic research and more than 20 years of experience in R&D and as a biotech CEO. He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization. In his new role with DDF, Dr. Santarelli will use his scientific and strategic expertise…

    BOSTON and LONDON, May 5, 2021 /PRNewswire/ -- The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, announces the appointment of Luca Santarelli, M.D., as new Chair of its Scientific Advisory Board (SAB). 

    Dr. Santarelli is an entrepreneurial pharmaceutical executive with a background in academic research and more than 20 years of experience in R&D and as a biotech CEO. He has led drug programs in the areas of neuroscience, rare diseases, ophthalmology, metabolic and G.I., spanning the value chain from discovery research to commercialization. In his new role with DDF, Dr. Santarelli will use his scientific and strategic expertise to advise on DDF's investment pipeline and portfolio strategy, provide input on its most advanced investment opportunities, and support to existing portfolio companies.

    Dr. Christian Jung, Partner at The Dementia Discovery Fund, said, "Dr. Santarelli brings scientific excellence, vast industry experience and a deep understanding of venture capital combined with a strong entrepreneurial spirit to our Scientific Advisory Board; we are delighted that he has agreed to become its Chair. I am confident that, in this role, he will provide outstanding guidance to continuously evolve DDF's scientific focus as we look to both source exciting new opportunities pursuing the translation of novel therapeutic concepts at the leading-edge of science and drive the growth and development of our existing portfolio."

    Dr. Luca Santarelli, said, "I am honored to be appointed Chair of DDF's world-class Scientific Advisory Board. DDF is building a portfolio of highly innovative companies in the dementia space and it is clear that technological innovation and better biological understanding of neurological diseases is presenting new opportunities to create ground-breaking companies and progress the development of new therapies in this important area. I very much look forward to working with the SAB and DDF's partners and portfolio companies on this exciting mission."

    Luca Santarelli, M.D.

    Dr. Santarelli is the CEO of VectivBio (NASDAQ:VECT), a clinical-stage rare disease company he founded after serving as CEO and co-founder of Therachon AG, which was acquired by Pfizer in 2019 for $810 million.

    Prior to Therachon, Dr. Santarelli was Venture Partner at Versant Ventures, which he joined after 12 years at Roche, most recently serving as the Senior Vice President and Head of Neuroscience, Ophthalmology and Rare Diseases. At Roche, he advanced over 20 new molecular entities (NMEs) to the clinic, various NMEs to registration studies including gantenerumab in Alzheimer's disease and spearheaded the development of several drug candidates that have now reached approval, including ocrelizumab in multiple sclerosis and risdiplan in spinal muscular atrophy. Dr. Santarelli also provided strategic and operational leadership for many of the Roche external biotech collaborations and helped instill a more entrepreneurial culture in the broader R&D organization. During this period, he catalyzed the creation of Synosia, a spin-off from Roche developing innovative treatments for disorders of the Central Nervous System (CNS). Synosia was acquired by Biotie in 2011.

    Previously, he was a Research Scientist at Columbia University and a co-founder of BrainCells Inc., a company focused on the discovery of novel antidepressants that are able to stimulate the growth of new neurons, with Nobel laureates Eric Kandel, Rene Hen and Fred Gage.

    Dr. Santarelli completed his M.D. and Psychiatry Residency at the University of Turin, Italy, and a postdoctoral fellowship at Columbia University.

    Photo available on request

    About The Dementia Discovery Fund

    The Dementia Discovery Fund (DDF) is a £250m specialist venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias including Alzheimer's disease. The DDF brings significant capital and domain expertise to enable talented entrepreneurs to bring therapeutics addressing one of the world's largest unmet medical needs to the clinic – ultimately aiming to generate significant returns for its investors. The DDF is enabled by its networks and influential group of investors including some leading pharmaceutical companies (Biogen, Eli Lilly and Co., GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), along with AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK Government's Department of Health and Social Care, and the charity Alzheimer's Research UK. The Fund is managed by SV Health Investors. Learn more at www.TheDDFund.com

    About SV Health Investors

    SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow's healthcare breakthroughs. The SV family of funds invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.7 billion in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 200 companies with more than 90 of these having achieved successful acquisitions or IPOs.

    For more information, please see www.svhealthinvestors.com

    FOR MORE INFORMATION

    Dementia Discovery Fund

    Laurence Barker (Partner), Jonathan Behr (Partner), Christian Jung (Partner)

    Citigate Dewe Rogerson

    Sylvie Berrebi, Frazer Hall, Mark Swallow PhD



    Tel: +44 (0)20 7638 9571

     

    Cision View original content:http://www.prnewswire.com/news-releases/the-dementia-discovery-fund-appoints-luca-santarelli-md-a-proven-neuroscience-leader-as-the-new-chair-of-its-scientific-advisory-board-301284088.html

    SOURCE The Dementia Discovery Fund

    View Full Article Hide Full Article
  2. BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, ("Vectiv" or "VectivBio") (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the closing of its initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters' option to purchase an additional 1,250,000 ordinary shares, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $146.6 million. Vectiv's ordinary shares began trading on the Nasdaq Global Market under the ticker symbol "VECT" on…

    BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, ("Vectiv" or "VectivBio") (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the closing of its initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters' option to purchase an additional 1,250,000 ordinary shares, at a public offering price of $17.00 per share. The gross proceeds from the offering were approximately $146.6 million. Vectiv's ordinary shares began trading on the Nasdaq Global Market under the ticker symbol "VECT" on April 9, 2021. All of the ordinary shares were offered by Vectiv.

    BofA Securities, SVB Leerink and Credit Suisse acted as joint book-running managers for the offering. LifeSci Capital also acted as an underwriter for the offering.

    The offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from: may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at ; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6105 or by email at ; or Credit Suisse Securities (USA) LLC Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at .

    A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (the "SEC") on April 8, 2021. Copies of the registration statement can be accessed by visiting the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About VectivBio

    VectivBio (NASDAQ:VECT) is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio's product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

    Investors

    Graham Morrell

    Media

    Morgan Warners

    +1 202 295 0124



    Primary Logo

    View Full Article Hide Full Article
  3. BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, ("Vectiv" or "VectivBio") (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional…

    BASEL, Switzerland, April 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, ("Vectiv" or "VectivBio") (NASDAQ:VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need, today announced the pricing of its initial public offering of 7,500,000 ordinary shares at a public offering price of $17.00 per share. The gross proceeds to Vectiv, before deducting underwriting discounts and commissions and offering expenses, are expected to be $127.5 million. All of the ordinary shares are being offered by Vectiv. In addition, Vectiv has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary shares at the initial public offering price, less the underwriting discounts and commissions.

    Vectiv's shares are expected to begin trading on the Nasdaq Global Select Market on Friday, April 9, 2021 under the ticker symbol "VECT." The offering is expected to close on April 13, 2021, subject to customary closing conditions.

    BofA Securities, SVB Leerink and Credit Suisse are acting as joint book-running managers for the offering. LifeSci Capital is also acting as an underwriter for the offering.

    A registration statement relating to the shares being sold in this offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on April 8, 2021. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from BofA Securities, Attention: Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, or by telephone at (800) 294-1322, or by email at ; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6105 or by email at ; or Credit Suisse Securities (USA) LLC Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, or by telephone at (800) 221-1037 or by email at .

    This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

    Investors

    Graham Morrell

    Media

    Morgan Warners

    +1 202 295 0124



    Primary Logo

    View Full Article Hide Full Article
View All VectivBio Holding AG News